adalimumab vs metoprolol
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of adalimumab and metoprolol. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Humira
Lopressor, Toprol-XL
Idacio is a medicine that blocks a protein called TNF. It is used to treat several diseases, including arthritis and Crohn's disease.
Metoprolol is a beta-blocker medicine. It can lower blood pressure, reduce chest pain, and improve survival after a heart attack.
Idacio can help adults with rheumatoid arthritis by reducing joint pain and damage. It can also help children (2 years and older) with juvenile idiopathic arthritis. Idacio treats psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.
Metoprolol treats high blood pressure (hypertension). Lowering blood pressure reduces the risk of strokes and heart attacks. It also treats chest pain called angina. After a heart attack, it can help you live longer.
Idacio works by blocking a protein in your body called tumor necrosis factor (TNF). TNF can cause inflammation and damage in certain diseases. By blocking TNF, Idacio can reduce these symptoms.
Metoprolol blocks the effects of adrenaline on the heart. This makes the heart beat slower and with less force. As a result, blood pressure is lowered and the heart does not need as much oxygen.
- • Infections (like colds or sinus infections)
- • Injection site reactions (redness, itching, pain, or swelling)
- • Headache
- • Rash
- • Tiredness
- • Dizziness
- • Depression
- • Shortness of breath
- • Slow heart rate
- Pain 49,062
- Arthralgia 48,039
- Injection Site Pain 47,251
- Fatigue 39,111
- Rheumatoid Arthritis 35,573
- Fatigue 15,966
- Dyspnoea 14,128
- Diarrhoea 13,635
- Nausea 13,398
- Dizziness 11,699
Idacio can increase your risk of serious infections that could lead to hospitalization or death. Tell your doctor if you have any infections before starting Idacio. Idacio may also increase your risk of certain cancers, including lymphoma. Children and teens taking TNF blockers like Idacio have developed rare, aggressive cancers.
Stopping metoprolol suddenly can make chest pain worse or cause a heart attack. If you have heart failure, it could get worse. If you have asthma or other lung problems, avoid beta-blockers if possible.
Tell your doctor if you are pregnant or plan to become pregnant. Idacio can cross the placenta and may affect your baby's immune system. Talk to your doctor about vaccines for your baby if you took Idacio during pregnancy.
Tell your doctor if you are pregnant or plan to become pregnant. Metoprolol can cross the placenta, and may cause low blood pressure, low blood sugar, and a slow heart rate in the newborn. Talk to your doctor about the risks and benefits.
Also Compare, Nearby Drugs
Compare adalimumab with
How to Read This adalimumab vs metoprolol Comparison
adalimumab is classified in the TNF-Alpha Inhibitor (Biologic) drug class, while metoprolol sits within the Beta-Blocker class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, adalimumab has 219,036 submissions while metoprolol has 68,826. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for adalimumab or metoprolol.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.